The California-based startup, founded in 2017, has developed a computational biology platform that harnesses machine learning and parallel chemical synthesis to engineer macrocyclic peptides. These peptides can access targets that were previously considered undruggable, accelerating the drug discovery process and unlocking the potential of macrocycle drug discovery.